These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

175 related items for PubMed ID: 949985

  • 21. [Comparative studies of L-DOPA alone and combination with a peripheral DOPA decarboxylase inhibitor, benserazide-HCl, on Parkinson's disease--Part II: Pharmacokinetic study (author's transl)].
    Yokochi M, Kondo T, Hirayama K, Narabayashi H, Kuruma I.
    No To Shinkei; 1979 Apr; 31(4):339-48. PubMed ID: 454549
    [No Abstract] [Full Text] [Related]

  • 22. Levodopa alone and in combination with a peripheral decarboxylase inhibitor benserazide (Madopar) in the treatment of Parkinson's disease: A controlled clinical trial.
    Rinne UK, Birket-Smith E, Dupont E, Hansen E, Hyyppä M, Marttila R, Mikkelsen B, Pakkenberg H, Presthus J.
    J Neurol; 1975 Dec 02; 211(1):1-9. PubMed ID: 56427
    [Abstract] [Full Text] [Related]

  • 23. [Development of studies on the treatment of Parkinson syndromes using levodopa. I. Short- and medium-term (2 years) effects of the combination levodopa decarboxylase inhibitor].
    Rondot P, Ribadeau Dumas JL, Cardon P.
    Therapie; 1975 Dec 02; 30(5):653-66. PubMed ID: 769245
    [No Abstract] [Full Text] [Related]

  • 24. Inhibition of decarboxylase and levels of dopa and 3-O-methyldopa: a comparative study of benserazide versus carbidopa in rodents and of Madopar standard versus Madopar HBS in volunteers.
    Da Prada M, Kettler R, Zürcher G, Schaffner R, Haefely WE.
    Eur Neurol; 1987 Dec 02; 27 Suppl 1():9-20. PubMed ID: 3123242
    [Abstract] [Full Text] [Related]

  • 25. [Levodopa and decarboxylase inhibitors in Parkinson's disease].
    Gilland O.
    Lakartidningen; 1977 Jan 05; 74(1-2):37-40. PubMed ID: 318722
    [No Abstract] [Full Text] [Related]

  • 26. Levodopa with benserazide or carbidopa in Parkinson disease.
    Rinne UK, Mölsä P.
    Neurology; 1979 Dec 05; 29(12):1584-9. PubMed ID: 574221
    [Abstract] [Full Text] [Related]

  • 27. Open study of Madopar HBS, a new formulation of levodopa with benserazide, in 13 patients with Parkinson's disease and 'on-off' fluctuations.
    Quinn NP, Marion MH, Marsden CD.
    Eur Neurol; 1987 Dec 05; 27 Suppl 1():105-13. PubMed ID: 3322834
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. [Disappearance of the disordered postural regulation of cerebral circulation by the addition of benserazide in parkinsonism treated with L-dopa].
    Boismare F, Samson M, Pouliquen A, Hacpille L.
    Therapie; 1976 Dec 05; 31(5):615-22. PubMed ID: 1013953
    [No Abstract] [Full Text] [Related]

  • 30. Patient benefits of l-dopa and a decarboxylase inhibitor in the treatment of Parkinson's disease in elderly patients.
    Admani AK, Verma S, Cordingley GJ, Harris RI.
    Pharmatherapeutica; 1985 Dec 05; 4(2):132-40. PubMed ID: 4059292
    [Abstract] [Full Text] [Related]

  • 31. [Treatment of Parkinson's syndrome with L-dopa and a decarboxylase inhibitor].
    Lombardo L, de la Garza R, Ivan-Reynoso G.
    Arch Invest Med (Mex); 1974 Dec 05; 5(2):105-16. PubMed ID: 4433198
    [No Abstract] [Full Text] [Related]

  • 32. [The association of L-DOPA and Ro 4-4602 in the treatment of Parkinson's disease (author's transl)].
    Campanella G, Pennetta R.
    Riv Patol Nerv Ment; 1974 Oct 05; 95(5):673-5. PubMed ID: 4470267
    [No Abstract] [Full Text] [Related]

  • 33. Bromocriptine alone or associated with L-dopa plus benserazide in Parkinson's disease.
    Caraceni TA, Celano I, Parati E, Girotti F.
    J Neurol Neurosurg Psychiatry; 1977 Dec 05; 40(12):1142-6. PubMed ID: 591982
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Niacin depletion in Parkinsonian patients treated with L-dopa, benserazide and carbidopa.
    Bender DA, Earl CJ, Lees AJ.
    Clin Sci (Lond); 1979 Jan 05; 56(1):89-93. PubMed ID: 477187
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. [5 years of experience in the treatment of parkinsonism with L-dopa and its combination with Ro4-4602].
    Romero S, Chouza C, Gomensoro JB.
    Neurol Neurocir Psiquiatr; 1976 Jan 05; 17(4):239-54. PubMed ID: 1018727
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Single-dose studies of a slow-release preparation of levodopa and benserazide (Madopar HBS) in Parkinson's disease.
    Marion MH, Stocchi F, Malcolm SL, Quinn NP, Jenner P, Marsden CD.
    Eur Neurol; 1987 Jan 05; 27 Suppl 1():54-8. PubMed ID: 3322837
    [Abstract] [Full Text] [Related]

  • 40. Effect of L-dopa on polycythemia.
    Herishanu Y, Rosenberg P.
    J Am Geriatr Soc; 1977 May 05; 25(5):218-9. PubMed ID: 853205
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.